Advertisement

Signal-transduction therapy

A novel approach to disease management
  • Alexander Levitzki
Part of the EJB Reviews 1994 book series (EJB REVIEWS, volume 1994)

Abstract

In the past decade it has become apparent that many diseases result from aberrations in signaling pathways. These include proliferative diseases such as cancers, atherosclerosis and psoriasis and inflammatory conditions such as sepsis, rheumatoid arthritis and tissue rejection. These findings refocused the research of the medical community to seek new modalities for disease management which essentially consist of designing drugs which intercept cell signaling. In this review, the emerging success in using tyrosine kinase blockers and other signal interceptors, such as protein kinase C blockers, Ras blockers, Ca2+ signaling inhibitors and estrogen antagonists which inhibit growth of cancer cells in vitro and in vivo, will be discussed. These signal interceptors, especially tyrosine-kinase blockers, are also able to block inflammatory responses and the proliferation of vascular smooth muscle cells and psoriatic keratinocytes. The utility of signal interceptors in analyzing signal-transduction pathways is also discussed.

Keywords

Epidermal Growth Factor Receptor Autocrine Loop Dominant Negative Construct Psoriatic Keratinocytes Signal Interceptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

acyl2Gro

diacyl glycerol

CAI

carboxamide amino-imidazole

CTK

cellular tyrosine kinase (s)

EGF

epidermal growth factor

EGFR

epidermal-growth-factor receptor

FKBP

FK506-binding protein

InsP3

inositol trisphosphate

KDR

kinase insert domain-containing receptor

MAP

microtubule-associated protein

MAPK

microtubule-associated protein kinase

MAPKK

microtubule-associated protein kinase kinase

PDGF

platelet-derived growth factor

PDGFR

platelet-derived growth factor receptor

PKC

protein kinase C

PLC

phospholipase C

PTK

protein-tyrosine kinase (s)

RTK

receptor tyrosine kinase(s)

TGF

transforming growth factor

VEGF

vascular endothelial growth factor

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anafi, M., Gazit, A., Gilon, C., Ben-Neriah, Y. & Levitzki, A. (1992) Selective interactions of transforming and normal abl proteins with ATP, tyrosine copolymer substrates and tyrphostins, J. Biol. Chem. 267, 4518–4523.PubMedGoogle Scholar
  2. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y. & Levitzki, A. (1993) Tyrphostins-induced inhibition of p210 bcr abl tyrosine kinase activity induces K562 to differentiate, Blood 82, 3524–3529.PubMedGoogle Scholar
  3. Andrejauskas-Buchdunger, F. & Regenass, U. (1992) Differential inhibition of the epidermal growth-factor, platelet derived growth and protein kinase C mediated signal-transduction pathways by the staurosporine derivative CGP 41251, Cancer Res. 52, 5353–5358.PubMedGoogle Scholar
  4. Antoniades, H. N., Galanapoulos, T., Neville-Golden, J. & O’Hara, C. J. (1992) Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth-factor (PDGF) and PDGF receptor mRNAs and their protein products, Proc. Natl Acad. Sci. USA 89, 3942–3946.PubMedCrossRefGoogle Scholar
  5. Bartlett, R. R., Dimitrijevic, M., Mattar, T., Zielinski, T., Germann, T., Rude, E., Thoenes G. H., Kuchle, C. C., Schorlemmer, H. U. & Bremer, E. (1991) Leflunomide (HWA486) a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection, Agents Actions 32, 10–21.PubMedCrossRefGoogle Scholar
  6. Basu, A. & Lazo, J. S. (1992) Sensitization of human cervical carcinoma cells to ds-diamminedichloroplatinum (II) by bryostatin 1, Cancer Res. 52, 3119–3124.PubMedGoogle Scholar
  7. Basu, A. (1993) The potential of protein kinase C for anticancer treatment, Pharmacol. & Ther. 59, 257–280.CrossRefGoogle Scholar
  8. Berdel, W. E. (1993) Membrane interactive lipid as experimental anticancer drugs, Br. J. Cancer 64, 208–211.CrossRefGoogle Scholar
  9. Besalga, J., Norton, L., Masui, H., Papdilla, A., Caplar, K., Miller, W. H. & Mendelsohn, J. (1993) Antitumor effects of doxorubicin in combination with anti-EGF receptor monoclonal antibodies, J. Natl Cancer Inst. 85, 1327–1333.CrossRefGoogle Scholar
  10. Betsholtz, C., Johnson, A., Heldin, C. H. & Westermark, B. (1986) Efficient reversion of simian sarcoma virus-transformation and inhibition of growth-factors induced mitogenesis by suramin, Proc. Natl Acad. Sci. USA 83, 6490–6498.CrossRefGoogle Scholar
  11. Bishop, J. M. (1991) Molecular themes in oncogenesis, Cell 64, 235–248.PubMedCrossRefGoogle Scholar
  12. Bos, J. L. (1989) Ras oncogenes in human cancer: a review, Cancer Res. 49, 4682–4689.PubMedGoogle Scholar
  13. Bosner, R. W., Thomson, N. T., Randal, R. W., Tateson, J. E., Spacey, G. D., Hodson, H. F. & Garland, L. G. (1991) Deme-thoxyviridin and wortmannin block phospholipase C at D activation in the human neutrophil, Br. J. Pharmacol. 103,1237–1241.Google Scholar
  14. Brunner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E. & Clarke, R.(1993) A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780, Cancer Res. 53, 3229–3232.PubMedGoogle Scholar
  15. Buchdunger, E., Trinks, U., Mett, H., Regenass, U., Müller, M., Meyer, T., McGlynn, E., Pinna, L. A., Traxler, P. & Lydon, N. B. (1993) 4,5-Dianilinophathalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth-factor receptor signal-transduction pathway and potent in vivo antitumor activity, Proc. Natl Acad. Sci. USA 91, 2334–2338.CrossRefGoogle Scholar
  16. Burke, T. R. Jr, Ford, H., Osherov, N., Levitzki, A., Stefanova, I., Horak, I. D. & Marquez, V. E. (1992) Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors, Bioorg. & Chem. Lett. 2, 1771–1774.CrossRefGoogle Scholar
  17. Cole, K. & Kohn, E. (1994) Calcium mediated signal-transduction: biology, biochemistry and therapy, Cancer Metastasis Rev. 13, 31–44.PubMedCrossRefGoogle Scholar
  18. Dauvois, S., White R. & Parker, M. G. (1993) The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling, J. Cell Sci. 106, 1377–1388.PubMedGoogle Scholar
  19. DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson E., Powsett, M., Mansei, F. E. & Blarney, R. U. (1994) Investigation of a new antiestrogen (ICI 182 780) in women with primary breast cancer, Cancer Res. 54, 408–416.PubMedGoogle Scholar
  20. Dickson, R. B., Salomon, D. S. & Lippman, M. E. (1992) Tyrosine kinase-nuclear proto-oncogene interactions in breast cancer, Cancer Treat. Res. 61, 249–273.PubMedCrossRefGoogle Scholar
  21. Dive, C., Evans, C. A. & Whetton, A. D. (1992) Induction of apoptosis. New targets for cancer chemotherapy, Semin. Cancer Biol. 3, 417–427.PubMedGoogle Scholar
  22. Drebin, J. A., Link, V. C., Stem, D. F. & Weinberg, R. A. (1985) Down modulation of an oncogenic protein product and reversion of the transformed phenotype by monoclonal antibodies, Cell 41, 695–706.CrossRefGoogle Scholar
  23. Drebin, J. A., Link, V. C., Weinberg, R. A. & Green, M. I. (1986) Inhibition of tumor growth by monoclonal antibody reactive with an oncogene encoded tumor antigen, Proc. Natl Acad. Sci. USA 83, 9129–9133.PubMedCrossRefGoogle Scholar
  24. Dreicer, R. & Wilding, G. (1992) Steroid hormone agonists and antagonists in the treatment of cancer, Cancer Invest. 10, 27–41.PubMedCrossRefGoogle Scholar
  25. Dumont, D. J., Yamaguchi, T. R, Conlon, R. A., Rossant, J. & Breitman, M. L. (1992) Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors, Oncogene 7, 1471–1480.PubMedGoogle Scholar
  26. Eisenberger, M. A., Reyno, L. M., Jodrell, D. I., Sinibaldi, V. W., Tkaczuk, K. H., Sridahara, R. & Zuhawski, E. (1993) Suramin, an active drug for prostate cancer: interim observations in a phase 1 clinical trial, J. Natl Cancer. Inst. 85, 611–621.PubMedCrossRefGoogle Scholar
  27. Fan, Z., Baselga, J., Masui, M. & Mendelsohn, J. (1993) Antitumor effect of anti-EGF receptor monoclonal antibody plus cis-diami- nodichloroplatinum as well established A431 cell xenografts, Cancer Res. 53, 4637–4642.PubMedGoogle Scholar
  28. Fearon, E. R. & Vogelstein, B. A (1990) Genetic model for colorectal tumorgenesis, Cell 61, 759–767.PubMedCrossRefGoogle Scholar
  29. Felder, C. C., Ma, A. L., Liotta, L. A. & Kohn, E. C. (1991) The antiproliferative and antimetastatic compound LG51582 inhibits muscarinic acetylcholine receptor stimulated calcium influx and arachidonic acid release, J. Pharmacol. Exp. Ther. 257, 967–971.PubMedGoogle Scholar
  30. Felder, C. C., MacArthur, L., Ma, A. L., Gusovsky, F. & Kohn, E. C. (1993) Tumor-suppressor function of muscarinic acetylcholine receptors is associated with activation of receptor-operated calcium influx, Proc. Natl Acad. Sci. USA 90, 1706–1710.PubMedCrossRefGoogle Scholar
  31. Fischei, L., Barbe, V., Berlion, M., Farmento, R, Berille, J., Bizzari, J. R & Milano, G. (1993) Tamoxifen enhances the cytotoxic effects of the nitrosouzea folemustine. Results in human melanoma lines, Eur. J. Cancer 29, 2269–2273.CrossRefGoogle Scholar
  32. Fu, T., Okaro, Y. & Nozawa, Y. (1992) Differential pathway (phospholipase C and phospholipase D) of bradikynin-induced biphasic 1,2-diacylglycerol formation in non-transformed NIH 3T3 fibroblasts involvement of intracellular Ca2+ in phosphatidylcholine breakdown, Biochem. J. 283, 347–354.PubMedGoogle Scholar
  33. Garcia, A. M., Rowell, C., Ackerman, K., Kowalczyk, J. J. & Lewis M. D. (1993) Peptidomimetic inhibitors of Ras famesylation and function in whole cells, J. Biol. Chem. 268, 18415–18418.PubMedGoogle Scholar
  34. Gazit, A., Yaish, P., Gilon, C. & Levitzki, A. (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors, J. Med. Chem. 32, 2344–2352.PubMedCrossRefGoogle Scholar
  35. Gazit,, A., Osherov, N., Posner, I., Yaish, R., Poradosu, E., Gilon, C. & Levitzki, A. (1991) Tyrphostins II: heterocyclic and a- substituted benzonemaloronitrile tyrphostins as potent inhibitors of EGF Receptor and ErbB2/neu tyrosine kinases, J. Med. Chem. 34, 1897–1907.CrossRefGoogle Scholar
  36. Gazit, A., Osherov, N., Posner, I., Bar-Sinai, A., Gilon, C. & Levitzki, A. (1993) Tyrphostin 3. Structure-activity relationship studies of α-substituted benzylidenemalononitrile 5-S-aryl- tyrphostins, J. Med. Chem. 36, 3556–3564.PubMedCrossRefGoogle Scholar
  37. Gesualdo L., Ranierei E., Pannarale G., Di Paolo, S. & Schena F. P. (1993) Platelet-derived growth-factor and proliferative glomerulonephritis, Kidney Int. Suppl. 39, 86–89.Google Scholar
  38. Gillespie, J., Dye, J. F., Schachtor, M. & Guillou, P. J. (1992) Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors, Br. J. Cancer 68, 1122–1126.CrossRefGoogle Scholar
  39. Grunicke, H. H. & Überall, F. (1992) Protein kinase C modulation, Semin. Cancer Biol. 3, 351–360.PubMedGoogle Scholar
  40. Harwerth, I. M., Wels, W., Schlegel, J., Muller, M. & Hynes, N. E. (1993) Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth, Br. J. Cancer 68, 1140–1145.PubMedCrossRefGoogle Scholar
  41. Hashimoto, K. & Yoshikawa, K. (1992) The growth regulation of keratinocytes, J. Dermatol. 19, 648–651.PubMedGoogle Scholar
  42. Heitman, J., Mowa, N. R. & Hall, M. N. (1992) Proline isomerases at the crossroads of protein folding, signal-transduction and immunosuppression, New Biologist 4, 448–460.PubMedGoogle Scholar
  43. Henrikson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C. H., Westermark, B. & Nister, M. (1992) Platelet-derived growth-factor and its receptor in human glioma tissue. Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops, J. Neurol. Sci. Ill, 119–133.Google Scholar
  44. Hornung, R. L., Pearson, J. W., Beckman, M. & Longo, D. L. (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity, Cancer Res. 52, 101–107.PubMedGoogle Scholar
  45. Hu, F., Verani, M., DeLuise, M., Wakeling, A., Sutherland, R., Watts, C. K. & Zalcberg, J. R. (1993) Circumvention of tamoxifen resistance by the pure antiestrogen ICI 182,780, Int. J. Cancer 55, 873–876.PubMedCrossRefGoogle Scholar
  46. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D. & Marsters, J. C. Jr (1993) Benzodiazepine peptidomimetics: potent inhibitors of ras famesylation in animal cells, Science 260, 1937–1942.PubMedCrossRefGoogle Scholar
  47. Kashles, O., Yarden, Y., Fischer, R., Ullrich, A. & Schlessinger, J. (1991) A dominant negative mutation suppresses the function of normal EGF receptors by heterodimerization, Mol. Cell. Biol. 11, 1459–1463.Google Scholar
  48. Kaur, G., Gazit, A., Levitzki, A., Stowe, E., Cooney, D. A. & Sausville, E. A. (1994) Tyrphostin induced growth inhibition: correlation with effect on p210bcr abl tyrosine autokinase activity in K562 chronic myelogenous leukemia, Anticancer Drugs 5, 213–222.PubMedCrossRefGoogle Scholar
  49. Kern, J. A., Torney, L., Weiner, D., Gazdar, A., Shepard, H. M. & Fendly, B. (1993) Inhibition of human lung cancer cell line growth by an anti-pl85Her-2 antibody, Am. J. Respir. Cell Mol. Biol. 9, 4.Google Scholar
  50. Kobayashi, E., Nakano, H., Morimoto, M. & Tamaoki, T. (1989) Calphostin C (UCN 1028c) a novel microbial compound is highly potent and specific inhibitor of protein kinase C, Biochem. Biophys. Res. Commun. 159, 548–553.PubMedCrossRefGoogle Scholar
  51. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A. & Gibbs, J. B. (1993) Selective inhibition of ras-dependent transformation by a famesyltransferase inhibitor, Science 260, 1934–1937.PubMedCrossRefGoogle Scholar
  52. Kohn, E. C., Felder, C. C., Jacobs, W., Holmes, K. A., Day, A. Freer, R. & Liotta, L. A. (1994) Stmcture-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI, Cancer Res. 54, 935–942.PubMedGoogle Scholar
  53. Kohn, E. K. & Liotta, L. A. (1990) L651582 a novel antiproliferative and antimetastasis agent, J. Natl Cancer Inst. 82.Google Scholar
  54. Kohn, E. K., Sandeen, M. A. & Liotta, L. A. (1992) In vivo efficacy of a novel inhibitor of selected signal-transduction pathways including calcium, arachidonate, and inositol phosphates, Cancer Res. 52, 3208–3212.PubMedGoogle Scholar
  55. Kore, M., Chandrasekar, B., Yamanaka, Y., Fries, H., Buchier, M. & Beger, H. G. (1992) Overexpression of the epidermal growth- factor receptor in human pancreatic cancer is associated with concomitant increase in the level of epidermal growth-factor and TGFa, J. Clin. Invest. 90, 1352–1360.CrossRefGoogle Scholar
  56. Kovalenko, M., Gazit, A., Böhmer, A., Rorsman, C., Rönnstrand Heldin, C. H., Waltenberger, J., Böhmer, F-D. & Levitzki, A. (1994) Selective PDGF receptor kinase blockers reverse sis- transformation, Cancer Res., in the press.Google Scholar
  57. Kumabe, T., Sohma, Y., Kayama, T., Yoshimoto, T. & Yamamoto, T. (1992) Amplification of PDGFR, a gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin, Oncogene 7, 627–633.PubMedGoogle Scholar
  58. Larsen, A. K. (1993) Suramin - an anticancer dmg with unique biological effects, Cancer Chemother. Pharmacol. 32, 96–98.PubMedCrossRefGoogle Scholar
  59. Ledwith, B. J. (1992) Reversal of transformed phenotypes by antisense fos, Ann. NY Acad. Sci. 660, 124–135.PubMedCrossRefGoogle Scholar
  60. Lee, B. A. & Donoghue, D. J. (1992) Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal-transduction, J. Cell. Biol. 118, 1057–1070.PubMedCrossRefGoogle Scholar
  61. Levitzki, A. (1992) Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal-transduction, FASEB J. 6, 3275–3282.PubMedGoogle Scholar
  62. Lewis, G. D., Figari, I., Fendly, B., Wong, W. L., Carter, P., Gorman, C. & Shepard, H. M. (1993) Differential responses of human tumor cell lines to anti-pl85Her-2 monoclonal antibodies, Cancer Immunol. Immunother. 37, 255–263.PubMedCrossRefGoogle Scholar
  63. Lin, P. S., Pettit, G. R. & Gewitz, D. A. (1992) Potentiation of 1-ß- D-arabinofuranosylacytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA, Cancer Res. 52, 6270–6278.PubMedGoogle Scholar
  64. Litherland, S. & Jackson, I. M. (1988) Treatment of early breast cancer, vol. 1, Oxford, U. K. Oxford University Press. Early breast cancer trialist’s collaborative group, Cancer Treat. Rev. 15, 183–194.PubMedCrossRefGoogle Scholar
  65. Love, R. R. & Korolchouk, V. (1993) Tamoxifen therapy in breast cancer control worldwide, Bull. World Health Organ. 71, 795803.Google Scholar
  66. Luttrell. D. K., Lee, A., Lansing, T. G., Orasty, R. M., Willard, D., Luther, M. & Rodriguez, M. (1994) Involvement of RP60C-Src with two major signaling pathways in human breast cancer, Proc. Natl Acad. Sci. USA 91, 83–87.PubMedCrossRefGoogle Scholar
  67. McClay, E. F., Albright, K. D., Jones, J. A., Christen, R. D. & Howell, S. B. (1993) Tamoxifen modulation of dsplatin cytotoxicity in human malignancies, Int. J. Cancer 55, 1018–1022.PubMedCrossRefGoogle Scholar
  68. Margolis, B., Phee, S.-G., Felder, S., Lyall, R., Levitzki, A., Ullrich, A., Zilberstein, A. & Schlessinger, J. (1989) EGF induces tyrosine phosphorylation of phospholipase CD: a potential mechanism for EGF-receptor signaling, Cell 57, 1101–1107.PubMedCrossRefGoogle Scholar
  69. Mauro, A., Bulfone, A., Turco, E. & Schiffer, D. (1991) Coexpression of platelet-derived growth factor (PDGF) B chain and PDGF B-type receptor in human gliomas, Child’s Nerv. Syst. 7 (8), 432–436.CrossRefGoogle Scholar
  70. Mendelsohn, J. (1992) Epidermal growth factor as a target for therapy with anti-receptor monoclonal antibodies, Monogr. Natl Cancer. Inst. 13, 125–131.PubMedGoogle Scholar
  71. Meyer, T., Regenass, U., Fabbro, D., Alteri E., Rösel, J., Müller, M., Carvatti, G. & Matter, A. (1989) A derivative of staurosporine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative and in vivo antitumor activity, Int. J. Cancer 43, 851–856.PubMedCrossRefGoogle Scholar
  72. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Möller, N. P. H, Risau, W. & Ullrich, A. (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis, Cell 72, 835–846.PubMedCrossRefGoogle Scholar
  73. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. (1993) Growth inhibited in vivo by a dominant negative Flk-1 mutant, Nature 367, 576–579.CrossRefGoogle Scholar
  74. Motzer, R. J., Nanus, D. M., O’Moore, P., Scher, H. I., Bajarin, D. F., Reuter, U., Tong, W. P. & Iversen, J. (1992) Phase II trial of suramin in patents with advanced renal cell carcinoma: Treatment results, pharmacokinetics and tumor growth-factor expression, Cancer. Res. 52, 5775–5779.PubMedGoogle Scholar
  75. Naramura, M., Gillies, S. D., Mendelsohn, J., Reisfeld, R. A. & Mueller, R. M. (1993) Therapeutic potential of chimeric and murine anti-EGF receptor antibodies in a metastasis model for human melanoma, Cancer Immunol. Immunother. 37, 343–349.PubMedCrossRefGoogle Scholar
  76. Novogrodsky, A., Vanichkin, A., Patya, M., Gazit, A., Osherov, N. & Levitzki, A. (1994) Prevention of lipopolysaccharide-in- duced lethal toxicity by tyrosine kinase inhibitors, Science 264, 1319–1322.PubMedCrossRefGoogle Scholar
  77. Ohmichi, M., Pang, L., Ribon, V., Gazit, A., Levitzki, A. & Saltiel, A. R. (1993) The tyrosine kinase inhibitor tyrphostin blocks the cellular action of nerve growth-factor, Biochemistry 32, 46504658.CrossRefGoogle Scholar
  78. Olivera, A. & Spiegel, S. (1993) Sphingosine-1 -phosphate as second messenger in cell proliferation induced by PDGF an FCS mitogens, Nature 365, 557–560.PubMedCrossRefGoogle Scholar
  79. Onoda, T., Linuma, H., Sasaki, Y., Hamada, M., Isshiki, K., Naganawa, H., Takeuchi, T., Tatsuta, K. & Umezawa, K. (1989) Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus, J. Natl Prod. (Lloydia) 52, 1252–1257.CrossRefGoogle Scholar
  80. Osherov, N., Gazit, A., Gilon, C. & Levitzki, A. (1993) Selective inhibition of the EGF and Her-2/Neu receptors by tyrphostins, J. Biol. Chem. 268, 11134–11142.PubMedGoogle Scholar
  81. Osherov, N. (1994) Ph. D. thesis, The Hebrew University of Jerusalem, Israel.Google Scholar
  82. Osherov, N. & Levitzki, A. (1994) Epidermal growth factor dependent activation of sre family kinases, Eur. J. Biochem. 225, 1047–1053.PubMedCrossRefGoogle Scholar
  83. Padeh, S., Levitzki, A., Gazit, A., Mills, G. B. & Roifman, C. M. (1991) Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation, J. Clin. Investigation 87, 1114–1118.CrossRefGoogle Scholar
  84. Pai, L. M. & Pastan, I. (1993) The use of immunotoxins for cancer therapy, Eur. J. Cancer 29, 1606–1609.CrossRefGoogle Scholar
  85. Petit, G. R. (1991) The bryostatins, Fortschr. Chem. Org. Naturst. 57, 153–195.CrossRefGoogle Scholar
  86. Posner, I., Engel, M., Gazit, A. & Levitzki, A. (1994) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program, Mol. Pharmacol. 45, 673–683.PubMedGoogle Scholar
  87. Prendville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stem, P., McDermott, R. & Potter, M. (1992) A phase I study of intravenous bryostatinl in patients with advanced cancer, J. Cell Physiol. 155, 301–312.Google Scholar
  88. Razakis-Adocke, M., Femley, R., Wade, J., Pawson, T. & Bowtell, C. (1993) The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator in Sosl, Nature 363, 83–85.CrossRefGoogle Scholar
  89. Roifman, C., Mills, G. B., Chin, K., Gazit, A., Gilon, C. & Levitzki, A. (1991) Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus cowen I, J. Immunol. 146, 2965–2971.PubMedGoogle Scholar
  90. Ross, R. C. (1993) The pathogenesis of atherosclerosis: perspective for the 1990’s, Nature 302, 801–809.CrossRefGoogle Scholar
  91. Rubin, K., Terracio, L., Rönnstrand, L., Heldin, C. H. & Klareskog, L. (1988) Expression of platelet-derived growth-factor receptors is induced on connective tissue cells during chronic synovial inflammation, Scand. J. Immunol. 27, 285–294.PubMedCrossRefGoogle Scholar
  92. Schreiber, S. L. (1991) Chemistry and biology of immunophilins and their immunosuppressive ligands, Science 251, 283–287.PubMedCrossRefGoogle Scholar
  93. Schreiber, S. L. (1992) Immunophilin sensitive protein phosphatase action in cell signaling pathways, Cell 70, 365–368.PubMedCrossRefGoogle Scholar
  94. Schreiber, S. L. & Crabtree, G. R. (1992) The mechanism of action of cyclosporine A and FK 506, Immunol. Today 13, 136–141.PubMedCrossRefGoogle Scholar
  95. Schuchter, L. M., Esa, A. H., May, S., Laulis, M. K., Pettit G. R. & Hess, A. D. (1991) Successful treatment of murine melanoma with bryostatin 1, Cancer Res. 51, 682–687.PubMedGoogle Scholar
  96. Segal, M., Willumsen, B. & Levitzki, A. (1993) Residues crucial for Ras interaction with GDP-GTP exchangers, Proc. Natl Acad. Sci. USA 90, 5564–5568.PubMedCrossRefGoogle Scholar
  97. Shamah, S. M., Stilles, C. D. & Gaha, A. (1993) Dominant negative mutants of PDGF revert the transformed phenotype of human astrocytoma cells, Mol. Cell. Biol. 13, 7203–7212.PubMedGoogle Scholar
  98. Shaw, R. J., Benedict, S. H., Clark, R. A. & King, T. E. (1991) Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma, Am. Rev. Respir. Dis. 143, 167–173.PubMedGoogle Scholar
  99. Shepard, M. H., Lewis, G. D., Samp, J. C., Fondby, B. M., Maneval, B., Mardenti, J., Figari, I. & Kotts, C. E. (1991) Monoclonal antibody therapy of human cancer: taking the Her2 proto-oncogene to the clinic, J. Clin. Immunol. 11, 117–127.PubMedCrossRefGoogle Scholar
  100. Shirasawa, S., Fumse, M., Yokoyama, N. & Sasazuki, T. (1993) Altered growth of human colon cancer cells disrupted at activated Kiras, Science 260, 85–88.PubMedCrossRefGoogle Scholar
  101. Sigal, N. H. & Dumont, F. J. (1992) Cyclosporine, FK-506 and rapamycin: pharmacological probes of lymphocyte signal-transduction, Annu. Rev. Immunol. 10, 519–560.PubMedCrossRefGoogle Scholar
  102. Slamon, D. J., Godolphin, W., Lovell, J. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. & Press, M. F. (1989) Studies of the Her-2/Neu proto-oncogene in human breast and ovarian cancer, Science 244, 707–712.PubMedCrossRefGoogle Scholar
  103. Speir, E. & Epstein, S. E. (1992) Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen, Circulation 86, 538–547.PubMedGoogle Scholar
  104. Stacey, D. W., DeGudicibus, S. R. & Smith, S. R. (1987) Cellular Ras Activity and tumor cell proliferation, Exp. Cell. Res. 171, 232–242.PubMedCrossRefGoogle Scholar
  105. Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y. & Sela, M. (1991) Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth, Proc. Natl Acad. Sci. USA 88, 8691–8695.PubMedCrossRefGoogle Scholar
  106. Stefanova, I., Corcoran, M. L., Horak, E. M., Wahl, L. M., Bolen, J. B. & Horak, I. D. (1993) Lipopolysaccharide induces activation of CD14 associated protein kinase p53/56lyn, J. Biol. Chem. 268, 20725–20728.PubMedGoogle Scholar
  107. Strawn, L. M., Mann, E., Eiliger, S. S., Chu, L. M., Germain, L. L., Niederfellner, G., Ullrich, A. & Shawver, L. K. (1994) Inhibition of glioma cell growth by a truncated platelet-derived growth factor-β receptor, J. Biol. Chem. 269, 21215–21222.PubMedGoogle Scholar
  108. Torp, S. H., Hesleth, E., Rugan, L., Stolan, S., Dalen, A. & Unsgaard, G. (1992) Expression of the epidermal growth-factor receptor gene in human brain metastases, APMIS 100, 713–719.PubMedCrossRefGoogle Scholar
  109. Tuttle, T. M., Inge, T. H., Bethke, K. R, McCrady, C. W., Pettit, G. R. & Bear, H. D. (1992) Activation of growth of murine tumor specific T-cells which have in vivo activity with bryostatin 1, Cancer Res. 52, 58–553.Google Scholar
  110. Tuzi, N. L., Ventor, D. J., Kumar, S., Staddon, S. L., Lemoine, N. R. & Gullick, W. J. (1991) Expression of growth factor receptors in human brain tumors, Br. J. Cancer 63, 227–233.PubMedCrossRefGoogle Scholar
  111. Ullrich, A. & Schlessinger, J. (1990) Signal-transduction by receptors with tyrosine kinase activity, Cell 61, 203–212.PubMedCrossRefGoogle Scholar
  112. Utz, I., Hofer, S., Regeness, U., Hilbe, W., Thaler, J., Grunicke, H. & Hofmann, J. (1994) The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance, Int. J. Cancer 57, 104–110.PubMedCrossRefGoogle Scholar
  113. Van Rijswick, R. E., Cuitovic, E., Wagstaff, J. & Myers, C. E. (1993) Workshop on suramin with emphasis on prostate cancer, Eur. J. Cancer 29, 298–300.CrossRefGoogle Scholar
  114. Vassbotn, F. S., Andersson, M., Westermark, B., Heldin, C. H. & Ostman, A. (1993) Reversion of autocrine transformation by a dominant negative PDGF mutant, Mol. Cell. Biol. 13, 4066–4076.PubMedGoogle Scholar
  115. Vogod, T. E., Vansterkenbugo, E. I., Wilting, J. & Jansen, L. H. (1993) Recent research on the biological activity of suramin, Pharmacol. Rev. 45, 177–203.Google Scholar
  116. Wakeling, A. E., Dukes, M. & Bowler, J. (1992) A potent specific pure antiestrogen with clinical potential, Cancer Res. 51, 3867–3873.Google Scholar
  117. Weinberg, R. A. (1989) Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis, Cancer Res. 49, 3713–3721.PubMedGoogle Scholar
  118. Weinstein, S. L., Gold, M. R. & DeFranco, A. L. (1991) Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages, Proc. Natl Acad. Sci. USA 88, 4148–4156.PubMedCrossRefGoogle Scholar
  119. Williams, W. V., VonFeldt, J. M., Ramanujam, T. & Weiner, D. B. (1992) Tyrosine kinase signal-transduction in rheumatoid synovitis, Semin. Arthritis Rheum. 5, 317–329.CrossRefGoogle Scholar
  120. Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors, Science 242, 933–935.PubMedCrossRefGoogle Scholar
  121. Yoneda, T., Lyall, R., Alsine M. M., Pearsons, P. E., Spada, A. P., Levitzki, A., Zilberstein, A. & Mundy, G. R. (1991) The antiproliferative effects of tyrosine kinase inhibitor tyrphostin on a human squamous cell carcinoma in vitro and in nude mice, Cancer Res. 51, 4430–4435.PubMedGoogle Scholar
  122. Zhang, W., Nakashima, T., Sakai, N., Yamada, H., Okano, Y. & Nozawa, Y. (1992) Activation of phospholipase D by PDGF in rat C6 glioma cells: possible role in mitogenic signal-transduction, Neurol. Res. 14, 397–401.PubMedGoogle Scholar

Copyright information

© FEBS 1994

Authors and Affiliations

  • Alexander Levitzki
    • 1
    • 2
  1. 1.Department of Biological Chemistry, Institute of Life SciencesThe Hebrew University of JerusalemJerusalemIsrael
  2. 2.SUGEN, Inc.Redwood CityUSA

Personalised recommendations